Eventide Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Eventide Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,314,000	Closed	-$23.3M	–	156
2018 Q3	$23.3M	Buy	1,314,000 +964,000	+275%	+$16.6M	0.86%	41
2018 Q2	$4.83M	Hold	350,000	–	–	0.2%	94
2018 Q1	$3.18M	Buy	+350,000	New	+$1.93M	0.15%	96
2014 Q2	–	Sell	-98,000	Closed	-$2.33M	–	114
2014 Q1	$2.33M	Buy	98,000 +52,300	+114%	+$758K	0.36%	62
2013 Q4	$489K	Buy	+45,700	New	+$505K	0.15%	86

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Eventide Asset Management's ECYT Position: Q4 2018 in Review

Eventide Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,314,000 shares — an estimated $23.3M sold.

Eventide Asset Management first reported a position in ECYT in Q4 2013 and held it in 5 quarters. The position peaked at $23.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Eventide Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Eventide Asset Management sold 1,314,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $23.3M.
Eventide Asset Management first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 5 quarters.
Eventide Asset Management's Endocyte, Inc. Common Stock position peaked at $23.3M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.